Beyfortus: A New Milestone in RSV Prevention for Young Children
March 7, 2024
Beyfortus, a newly developed monoclonal antibody product by AstraZeneca and Sanofi, has shown a remarkable 90% effectiveness in preventing hospitalization from Respiratory Syncytial Virus (RSV) in young children during its first season of use in the United States, surpassing its clinical trial efficacy estimates. This first batch of real-world data, published in the CDC’s Morbidity and Mortality Weekly Report, highlights Beyfortus’s significant impact on reducing severe RSV-related health outcomes. Despite supply shortages and distribution challenges, approximately 40.5% of eligible babies received Beyfortus this winter. The drug, designed for universal use in young children with a single dose administration, represents a promising advancement in RSV prevention, potentially transforming the seasonal impact of the virus akin to the effects of rotavirus vaccines.
To read more, click here.
[Source: STAT, March 7th, 2024]
